Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges
PG Rubinstein, DM Aboulafia, A Zloza - Aids, 2014 - journals.lww.com
The incidence of AIDS-defining cancers (ADCs)–Kaposi sarcoma, primary central nervous
system lymphoma, non-Hodgkin lymphoma, and cervical cancer–although on the decline …
system lymphoma, non-Hodgkin lymphoma, and cervical cancer–although on the decline …
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and …
S Montoto, K Shaw, J Okosun, S Gandhi… - Journal of clinical …, 2012 - ascopubs.org
Purpose The prognosis of HIV-infected patients with non-Hodgkin lymphoma in the highly
active antiretroviral therapy (HAART) era approaches that of the general population when …
active antiretroviral therapy (HAART) era approaches that of the general population when …
Cancer in people living with HIV, version 1.2018, NCCN clinical practice guidelines in oncology
E Reid, G Suneja, RF Ambinder, K Ard… - Journal of the National …, 2018 - jnccn.org
People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the
general population and generally have a higher mortality due to delayed diagnoses …
general population and generally have a higher mortality due to delayed diagnoses …
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
PG Rubinstein, PC Moore, M Bimali, JY Lee… - The Lancet …, 2023 - thelancet.com
Background Brentuximab vedotin in combination with doxorubicin, vinblastine, and
dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin …
dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin …
Cancer in People with HIV
TA Odeny, V Fink, M Muchengeti… - Infectious Disease …, 2024 - id.theclinics.com
In this review, we provide an overview of the intersection between human immunodeficiency
virus (HIV) and cancer. Addressing cancer in the context of HIV requires consideration not …
virus (HIV) and cancer. Addressing cancer in the context of HIV requires consideration not …
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma
PG Rubinstein, PC Moore, MA Rudek, DH Henry… - Aids, 2018 - journals.lww.com
Objective: Brentuximab vedotin is a Food and Drug Administration approved anti-CD30
antibody drug conjugate potently active in Hodgkin lymphoma. Trials of brentuximab vedotin …
antibody drug conjugate potently active in Hodgkin lymphoma. Trials of brentuximab vedotin …
Brentuximab Vedotin with AVD for Stage II-IV HIV-Related Hodgkin Lymphoma, The Phase 2 Portion of AMC 085, a Multicenter Phase I/II Trial
PG Rubinstein, PC Moore, M Bimali… - The Lancet …, 2023 - pmc.ncbi.nlm.nih.gov
Background Brentuximab Vedotin (BV) in combination with doxorubicin, vinblastine, and
dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin …
dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin …
[PDF][PDF] Linfomas relacionados à AIDS: proposta de tratamento e interações com antirretrovirais
MA Almeida - 2017 - repositorio-bc.unirio.br
Introdução: O Linfoma não-Hodgkin (LNH) de células B de alto grau é considerado, desde
1985, como doença definidora de Síndrome da Imunodeficiência Adquirida (AIDS) após …
1985, como doença definidora de Síndrome da Imunodeficiência Adquirida (AIDS) após …
[引用][C] Tearing down the false walls to HIV cancer care
RF Little - Cancer, 2019 - Wiley Online Library
HIV serostatus is not a barrier to curative‐intent radiochemotherapy for women with cervical
cancer in Botswana. This model should be adopted for all HIV and cancer care worldwide.
cancer in Botswana. This model should be adopted for all HIV and cancer care worldwide.